1. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy
- Author
-
Nanashima, A., Omagari, K., Sumida, Y., Abo, T., Fukuoka, H., Takeshita, H., Hidaka, S., Tanaka, K., Terumitsu Sawai, Yasutake, T., Nagayasu, T., Mizuta, Y., Ohba, K., Ohnita, K., and Kadokawa, Y.
- Subjects
Adult ,Aged, 80 and over ,Male ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,SLiDe score ,Liver Neoplasms ,Middle Aged ,Prognosis ,Liver Function Tests ,Biomarkers, Tumor ,Humans ,Hepatectomy ,Female ,Aged ,Neoplasm Staging - Abstract
BACKGROUND/AIMS: A new prognostic staging system, the SLiDe (S, stage; Li, liver damage; De, des-gamma-carboxy prothrombin) score was recently proposed. We examined 207 HCC patients following hepatic resection to determine the usefulness of this staging system for HCC patients after surgery. METHODOLOGY: Disease-free and overall survival rates were calculated according to the Kaplan-Meier method, and differences between groups were tested for significance using the log-rank test. RESULTS: Regarding disease-free survival, there were no significant differences in survival between SLiDe score 0 vs 1, between score 2 vs 3, and between score 4 vs 5. There were significant differences between 0-1 vs 2-3 (p < 0.01) and between 2-3 vs 4-5 (p < 0.01). Regarding overall survival, there were no significant differences in survival between score 0 vs 1, between score 2 vs 3, and between score 4 vs 5. There were significant differences between 0-1 vs 2-3 (p < 0.05) and between 2-3 vs 4-5 (p < 0.01). CONCLUSIONS: The SLiDe score, a staging system that combines tumor factors, a tumor marker and hepatic function, might be a better predictor of prognosis in HCC patients who have undergone hepatic resection., Hepato-gastroenterology, 56(93), pp.1137-1140; 2009